BrightSpring Health Services’ BTSG Home and Community Pharmacy business is facing a meaningful revenue setback from the Inflation Reduction Act (IRA), but the company’s second-quarter performance suggests operational efficiency is helping sustain the profitability margin.
Revenues in the segment fell 8% year over year to $540 million, with management attributing part of the decline to an approximately $50 million IRA impact during the quarter, alongside the exit from certain uneconomic customers. For full-year 2026, BrightSpring expects the IRA to reduce Home and Community Pharmacy revenues by approximately $200 million.
The more important consideration for investors is the relatively limited impact on EBITDA. Management continues to expect the full-year EBITDA impact from the IRA at approximately $15 million, despite the $200 million revenue headwind. This indicates that the regulatory pricing changes are having a substantially greater effect on reported revenues than on profitability.
In the second quarter, Home and Community Pharmacy EBITDA increased year over year despite the external IRA and payer pressures. Management attributed the improvement to continued operational process enhancements and the deployment of new technologies.
Technology, automation and AI remain central to BrightSpring’s efficiency strategy. The company is using these tools across operational processes, while Lean initiatives and procurement improvements are contributing to efficiency generation. Management expects these investments to continue benefiting the business into 2027.
BrightSpring estimates that the 2027 IRA impact on Home and Community Pharmacy will be roughly 50% of the 2026 impact, while also pursuing regulatory, payer-contracting and operational measures to mitigate the pressure. Thus, although IRA pricing changes remain a revenue constraint, improving efficiency and a lower expected regulatory burden could help protect the segment’s profitability trajectory.
Peer Updates
Cardinal Health CAH has entered fiscal 2027 facing regulatory pressure from Inflation Reduction Act pricing changes, with WACC adjustments creating an estimated 500-basis-point Pharma revenue headwind. However, management expects little to no profit impact as service compensation and distribution agreements protect economics.
Cardinal Health continues working with manufacturers and customers to adapt to changing transaction models while leveraging long-term relationships for stability. Manufacturer pricing adjustments could affect revenue flows, but the company expects Pharma profitability to remain supported by brand and generic volumes and higher-margin Specialty operations. Overall, Cardinal Health appears positioned to absorb policy-driven revenue pressure without significant margin deterioration.
CVS Health's CVS pharmacy economics is already getting affected by the regulatory drug-price reductions, although the company did not separately quantify the IRA's specific margin impact. Pharmacy & Consumer Wellness revenues were pressured by regulatory-related price reductions on certain drugs, generic introductions and reimbursement pressure, while adjusted operating income still increased more than 10% year over year.
In Caremark, CVS is transitioning toward net-cost pricing models amid regulatory developments, with management emphasizing that the transition is intended to preserve the value delivered by the PBM. The company also expects to maintain margins at historical industry levels over time, supported by specialty pharmacy, generic penetration, purchasing economics and operational improvements.
BTSG’s Price Performance, Valuation and Estimates
Shares of BTSG have surged 57.4% year to date compared with the industry’s 3.8% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, BrightSpring Health Services trades at a forward price-to-earnings of 27.61X, above the industry average. It is also trading higher than its three-year median of 22.07X. BTSG carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BrightSpring Health Services’ 2026 earnings implies an 82% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BrightSpring Health Services, Inc. (BTSG): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).